Citadel Advisors
MTNB icon

Citadel Advisors’s Matinas BioPharma MTNB Stock Holding History

Citadel Advisors’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.46K Sell
15,465
-36,233
-70% -$23.3K ﹤0.01% 13505
2026
Q1 		$25.8K Sell
51,698
-14,036
-21% -$8.79K ﹤0.01% 12619
2025
Q4 		$38.5K Buy
+65,734
New +$77.5K ﹤0.01% 12142
2023
Q1 		– Sell
-1,042
Closed -$26.1K – 15196
2022
Q4 		$26.1K Buy
1,042
+626
+150% +$20.8K ﹤0.01% 12901
2022
Q3 		$13K Buy
+416
New +$16.3K ﹤0.01% 12204
2022
Q1 		– Sell
-2,361
Closed -$119K – 14223
2021
Q4 		$119K Sell
2,361
-1,336
-36% -$71.4K ﹤0.01% 12534
2021
Q3 		$241K Buy
+3,697
New +$160K ﹤0.01% 11559
2021
Q2 		– Sell
-6,294
Closed -$330K – 14125
2021
Q1 		$330K Buy
6,294
+4,155
+194% +$279K ﹤0.01% 10616
2020
Q4 		$145K Buy
2,139
+670
+46% +$31K ﹤0.01% 9968
2020
Q3 		$56K Sell
1,469
-868
-37% -$34.5K ﹤0.01% 9560
2020
Q2 		$90K Buy
+2,337
New +$89.6K ﹤0.01% 9052
2020
Q1 		– Sell
-556
Closed -$63K – 9960
2019
Q4 		$63K Buy
+556
New +$32.2K ﹤0.01% 8692
2019
Q1 		– Sell
-2,072
Closed -$61K – 9657
2018
Q4 		$61K Buy
+2,072
New +$81.3K ﹤0.01% 8436
2018
Q3 		– Sell
-225
Closed -$5K – 9530
2018
Q2 		$5K Sell
225
-267
-54% -$7.71K ﹤0.01% 8736
2018
Q1 		$19K Sell
492
-403
-45% -$21.3K ﹤0.01% 8131
2017
Q4 		$52K Buy
+895
New +$57.5K ﹤0.01% 7619
2017
Q3 		– Sell
-722
Closed -$61K – 7841
2017
Q2 		$61K Buy
+722
New +$96.9K ﹤0.01% 7049

Other funds holding MTNB

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HIW
Holos Integrated Wealth Kennett Square, Pennsylvania $214M AUM 14.99% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Citadel Advisors's MTNB Position: Q2 2026 in Review

Citadel Advisors reduced its Matinas BioPharma (MTNB) stake by 70% in Q2 2026, selling an estimated $23.3K and leaving 15,465 shares worth $9.46K. The position accounts for ﹤0.01% of the portfolio, ranked #13505.

Citadel Advisors first reported a position in MTNB in Q2 2017 and has held it in 17 quarters since. The position peaked at $330K in Q1 2021. 25 funds tracked by Wall St. Rank hold MTNB as of Q2 2026.

  • Citadel Advisors held 15,465 shares of Matinas BioPharma worth $9.46K as of Q2 2026.
  • Citadel Advisors sold 36,233 Matinas BioPharma shares in Q2 2026, an estimated $23.3K.
  • Matinas BioPharma made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13505 holding.
  • Citadel Advisors first reported a position in Matinas BioPharma in Q2 2017 and has held it in 17 quarters since.
  • Citadel Advisors's Matinas BioPharma position peaked at $330K in Q1 2021.
  • 25 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.